Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

What Was Tested

The trial (not phased) is built around Insulin (regular human).

Their goal is to compare a strict and permissive threshold.

It had two arms (groups): Strict Arm (active comparator) and Permissive (active comparator).

The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated).

The registry classes the interventions as drug.

More on the Plan

Pregnancy is a state of insulin resistance to ensure that the growing fetus has ample nutrition.

Gestational Diabetes (GDM) develops in pregnant patients with pancreatic dysfunction that leads to impairment of glucose tolerance.

The specific threshold value for initiation and up-titration of medical therapy is unknown.

However, there have been no randomized controlled trials of head-to-head comparison of different thresholds.

Who Took Part

Enrollment: 430 planned participants were the target.

It was open to women only aged from 18 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Live, non-anomalous fetus. Literacy in English, Spanish, Mandarin, or Arabic.

The full record lists 3 inclusion and 9 exclusion criteria; among the exclusions: \<18 years at edd; pre-existing diabetes or diagnosis of gdm before 24 weeks; multi-fetal gestation.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Insulin (regular human) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Insulin (regular human) group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Insulin (regular human) study: the participants and staff both knew the treatment.

It started in 2024-09-01 with completion listed for 2026-05.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Neonatal Composite Outcome (time frame: First 28 days of birth).

It also tracked 13 secondary outcomes, for example Neonatal Outcome: Gestational Age of Birth, Neonatal Outcome: APGAR Score, Neonatal Outcome: Birthweight, Neonatal Outcome: Brachial Plexus Injury, Neonatal Outcome: Respiratory distress and Neonatal Outcome: Admission to Neonatal intensive Care Unit.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Insulin (regular human) in 430 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin (regular human) compound page, all human trials.